Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 7/20 | 0.51 |
| ▸ | NMT2 | O60551 | 6/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29072167 | 1.00 | NMT1 (0.51) | NMT1NMT2SLC6A5TLR2KMT2A | |
| SCHEMBL24630329 | 0.95 | SLC6A5 (0.46) | NMT1NMT2SLC6A5KMT2APOLB | |
| SCHEMBL24630326 | 0.95 | SLC6A5 (0.46) | NMT1NMT2SLC6A5KMT2APOLB | |
| SCHEMBL29336456 | 0.93 | SLC6A5 (0.48) | NMT1NMT2SLC6A5KMT2APOLB | |
| SCHEMBL26616331 | 0.90 | FOLH1 (0.46) | NMT1NMT2SLC6A5KMT2APOLB | |
| SCHEMBL20450528 | 0.88 | SLC6A5 (0.50) | NMT1NMT2SLC6A5KMT2AITGB3 | |
| SCHEMBL20450527 | 0.88 | SLC6A5 (0.50) | NMT1NMT2SLC6A5KMT2AITGB3 | |
| SCHEMBL13997385 | 0.86 | CTSK (0.49) | KMT2APOLBITGB3ITGA2B | |
| SCHEMBL13997388 | 0.86 | CTSK (0.49) | KMT2APOLBITGB3ITGA2B | |
| SCHEMBL17445176 | 0.86 | CTSK (0.49) | KMT2APOLBITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-4274582-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | Osprey Biopharmaceuticals, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-116744944-A | Low-immunogenicity biotherapeutic medicine | 奥斯普瑞生物制药有限公司 | 2023-09-12 | — | — | CN | disclosed |
| WO-2022150726-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022150726-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | FCGR3B, CD47, IL2 | NMT1 3418/4885NMT2 2649/4885SLC6A5 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.